Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$256,907,646
New position
Shares Held
1,302,645
first reported quarter
Ownership
0.084%
of shares outstanding
% of Portfolio
0.23%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$13,746,234
CallShares
69,700
PutValue
$7,967,688
PutShares
40,400
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026MILLENNIUM MANAGEMENT LLC holds $2,000,798,301 across 16 Drug Manufacturers - General names. AZN ranks #2 (12.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
6,545,442 | $396,981,057 | |
| 2 | AZN |
Astrazeneca PLC
This page
|
1,302,645 | $256,907,646 | |
| 3 | LLY |
ELI LILLY & Co
|
275,989 | $253,846,402 | |
| 4 | MRK |
Merck & Co., Inc.
|
1,970,691 | $237,054,420 | |
| 5 | SNY |
Sanofi
|
3,440,654 | $165,770,709 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
1,180,760 | $164,562,521 | |
| 7 | ABBV |
AbbVie Inc.
|
675,757 | $146,970,389 | |
| 8 | JNJ |
Johnson & Johnson
|
575,707 | $140,725,819 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,967,688 | 40,400 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $13,746,234 | 69,700 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $256,907,646 | 1,302,645 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||